| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
17 abstracts from across the Company's portfolio and pipeline highlight new clinical and real-world data on major depressive disorder and treatment-resistant depression
New post-hoc analysis of CAPLYTA® (lumateperone) Phase 3 data evaluates the impact on sexual function in MDD, reinforcing potential to reset treatment expectations
European Union and United Kingdom sub-group analyses of Phase 3 data evaluate efficacy of adjunctive seltorexant compared to adjunctive quetiapine XR in MDD with insomnia symptoms
New data from post-hoc analysis of ESCAPE-TRD explores association of patient characteristics and remission with SPRAVATO® (esketamine) versus quetiapine XR in treatment-resistant depression
TITUSVILLE, N.J., Oct. 10, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today that 17 abstracts featuring new clinical and real-world data will be presented at the annual European College of Neuropsychopharmacology (ECNP) Congress, taking place October 11-14 in Amsterdam, The Netherlands. Presentations include the latest research from across the Company's neuropsychiatry portfolio, including major depressive disorder (MDD), treatment-resistant depression (TRD), and schizophrenia.
Posted In: JNJ
